The American Journal of Medicine
Volume 121, Issue 8, Supplement 2 , Pages S34-S42 , August 2008

Educating Patients About Lifestyle Modifications for Prostate Health

  • Mark A. Moyad, MD, MPH

      Affiliations

    • Department of Urology, University of Michigan Medical Center, Ann Arbor, Michigan, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Mark A. Moyad, MD, MPH, University of Michigan Medical Center, Department of Urology, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109-0330.
    • ,
  • Franklin C. Lowe, MD, MPH

      Affiliations

    • Department of Urology, St. Luke's Roosevelt Hospital and Columbia University College of Physicians and Surgeons, New York, New York, USA

References 

  1. Sarma AV, Wei JT, Jacobson DJ, et al. Comparison of lower urinary tract symptom severity and associated bother between community-dwelling black and white men: the Olmsted County Study of Urinary Symptoms and Health Status and the Flint Men's Health Study. Urology. 2003;61:1086–1091
  2. Arrighi HM, Metter EJ, Guess HA, Fozzard JL. Natural history of benign prostatic hyperplasia and risk of prostatectomy: the Baltimore Longitudinal Aging Study. Urology. 1991;38(suppl 1):4–8
  3. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474–479
  4. Kupelian V, Wei JT, O'Leary MP, et al. BACH Survey Investigators Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med. 2006;166:2381–2387
  5. Parsons JK, Carter HB, Partin AW, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006;91:2562–2568
  6. Michel MC, Heemann U, Schumacher H, Menlburger L, Goepel M. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol. 2004;172:1390–1393
  7. Clifford GM, Farmer RD. Drug or symptom-induced depression in men treated with α1-blockers for benign prostatic hyperplasia? (A nested case-control study). Pharmacoepidemiol Drug Saf. 2002;11:55–61
  8. Morton MS, Turkes A, Denis L, Griffiths K. Can dietary factors influence prostatic disease?. BJU Int. 1999;84:549–554
  9. Moyad MA. Lifestyle changes to prevent BPH: Heart healthy = prostate healthy. Urol Nurs. 2003;23:439–441
  10. Gibbons EP, Colen J, Nelson JB, Benoit RM. Correlation between risk factors for vascular disease and the American Urological Association Symptom Score. BJU Int. 2007;99:97–100
  11. Parsons JK. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol. 2007;178:395–401
  12. Lee S, Min HG, Choi SH, et al. Central obesity as a risk factor for prostatic hyperplasia. Obesity (Silver Spring). 2006;14:172–179
  13. Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol. 2002;168:599–604
  14. Platz EA, Kawachi I, Rimm EB, et al. Physical activity and benign prostatic hyperplasia. Arch Intern Med. 1998;158:2349–2356
  15. Witt DK. Health disparities in African American males. Prim Care. 2006;33:35–43
  16. Diaz VA. Hispanic male health disparities. Prim Care. 2006;33:45–60
  17. Jimbo M. Organizing preventive health care in men. Prim Care. 2006;33:237–246
  18. US Preventive Services Task Force. Guide to Clinical Preventive Services. 3rd edition. http://www.ahrq.gov/clinic/cps3dix.htmAccessed March 1, 2007
  19. Moyad MA. Dr. Moyad's A–Z List: Part 1. Seminars in Preventive and Alternative Medicine. 2005;1:23–49
  20. The Expert Panel. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) (Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)). JAMA. 2001;285:2486–2498
  21. Lee E, Park M-S, Shin C, et al. A high-risk group for prostatism: a population-based epidemiological study in Korea. Br J Urol. 1997;79:736–741
  22. Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol. 2001;39:151–158
  23. Sandfeldt L, Hahn RG. Cardiovascular risk factors correlate with prostate size in men with bladder outlet obstruction. Br J Urol Intl. 2003;92:64–68
  24. Berger AP, Bartsch G, Deibl M, et al. Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU Int. 2006;98:1038–1042
  25. Michel MC, Mehlbuger L, Schumacher H, Bressel HU, Goepel M. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol. 2000;163:1725–1729
  26. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol. 2007;51:199–206
  27. Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol. 2001;54:935–944
  28. Weisman KM, Larijani GE, Goldstein MR, Goldberg ME. Relationship between benign prostatic hyperplasia and history of coronary artery disease in elderly men. Pharmacotherapy. 2000;20:383–386
  29. Grundy SM, Cleeman JI, Marz NB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227–239
  30. Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, the National Heart, Lung, and Blood Institute, and the National High Blood Pressure Education Program Coordinating Committee Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252
  31. Yun AJ, Bazar KA, Lee PY, Gerber A, Daniel SM. The smoking gun: many conditions associated with tobacco exposure may be attributable to paradoxical compensatory autonomic responses to nicotine. Med Hypotheses. 2005;64:1073–1079
  32. Platz EA, Rimm EB, Kawachi I, et al. Alcohol consumption, cigarette smoking, and risk of benign prostatic hyperplasia. Am J Epidemiol. 1999;149:106–115
  33. Kupeli B, Soygur T, Aydos K, Ozdiler E, Küpelis S. The role of cigarette smoking in prostatic enlargement. Br J Urol. 1997;80:201–204
  34. Centers for Disease Control and Prevention. Tobacco Use Among Adults—United States, 2005. [serial online] MMWR Morbid Mortal Wkly Rep. 2006;55:1145–1148http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5644a2.htm Accessed March 1, 2008
  35. Centers for Disease Control and Prevention. Smoking & tobacco use: cessation [fact sheet]. Updated March 2007 http://www.cdc.gov/tobacco/data_statistics/Factsheets/cessation2.htmUpdated April 2008. Accessed March 1, 2008
  36. FDA approves novel medication for smoking cessation [press release]. FDA News [FDA Web site]. Rockville, MD: US Food and Drug Administration; May 11, 2006. Document no. P06-67. http://www.fda.gov/bbs/topics/NEWS/2006/NEW01370.htmlAccessed March 1, 2007
  37. Wu P, Wilson K, Dimoulas P, Mills EJ. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health. 2006;6:300
  38. Eldrup E, Lindholm J, Winkel P. Plasma sex hormones and ischemic heart disease. Clin Biochem. 1987;20:105–114
  39. Troisi RJ, Weiss ST, Parker DR. Relation of obesity and diet to sympathetic nervous system activity. Hypertension. 1991;17:669–677
  40. Hammarsten J, Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press. 1999;8:29–36
  41. Haslam D, Sattar N, Lean M. Obesity-time to wake up. BMJ. 2006;333:640–642
  42. Moyad MA. Current methods used for defining, measuring, and treating obesity. Semin Urol Oncol. 2001;19:247–256
  43. Zhu S, Heymsfield SB, Toyoshima H, Wang Z, Pietrobelli A, Heshka S. Race-ethnicity-specific waist circumference cutoffs for identifying cardiovascular disease risk factors. Am J Clin Nutr. 2005;81:409–415
  44. Moyad MA. Promoting Wellness for Prostate Cancer Patients. Ann Arbor, MI: JW Edwards Publishing; 2006;
  45. Moyad MA. The ABCs of Nutrition and Supplements for Prostate Cancer. Ann Arbor, MI: JW Edwards Publishing; 2003;
  46. Trojan TH, Mody K, Chain P. Exercise and colon cancer: primary and secondary prevention. Curr Sports Med Rep. 2007;6:120–124
  47. Kiningham RB. Physical activity and the primary prevention of cancer. Prim Care. 1998;25:515–536
  48. Haskell WL, Lee IM, Pate RR, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation. 2007;116:1081–1093
  49. Lee Y, Park K. Does physical activity moderate the association between depressive symptoms and disability in older adults?. Int J Geriatr Psychiatry. 2008;23:249–256
  50. Church TS, LaMonte MJ, Barlow CE, Blair SN. Cardiorespiratory fitness and body mass index as predictors of cardiovascular disease mortality among men with diabetes. Arch Intern Med. 2005;165:2114–2120
  51. Keen R. Osteoporosis: strategies for prevention and management. Best Pract Res Clin Rheumatol. 2007;21:109–122
  52. Wei M, Gibbons LW, Kampert JB, Nichaman MZ, Blair SN. Low cardiorespiratory fitness and physical inactivity as predictors of mortality in men with type 2 diabetes. Ann Intern Med. 2000;132:605–611
  53. Cheng JY, Ng EM, Ko JS, Chen RY. Physical activity and erectile dysfunction: meta-analysis of population-based studies. Int J Impot Res. 2007;19:245–252
  54. Giovannucci E, Rimm EB, Chute CG, et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol. 1994;140:989–1002
  55. Gann PH, Hennekens CH, Longcope C, Verhoek-Oftedahl W, Grodstein F, Stampfer MJ. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate. 1995;26:40–49
  56. Suzuki S, Platz EA, Kawachi I, Willett WC, Giovannucci E. Intakes of energy and macronutrients and the risk of benign prostatic hyperplasia. Am J Clin Nutr. 2002;75:689–697
  57. Fontana L, Klein S. Aging, adiposity, and calorie restriction. JAMA. 2007;297:986–994
  58. Heilbronn LK, de Jonge L, Frisard MI, et al. Pennington CALERIE Team Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial. JAMA. 2006;295:1539–1548
  59. Kristal AR, Chi C, Tangen CM, Goodman PJ, Etzioni R, Thompson IM. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer. 2006;106:320–328
  60. Joseph M, Harlow S, Wei J, et al. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol. 2003;157:906–914
  61. Bravi F, Bosetti C, Dal Maso L, et al. Macronutrients, fatty acids, cholesterol, and risk of benign prostatic hyperplasia. Urology. 2006;67:1205–1211
  62. Bravi F, Bosetti C, Dal Maso L, et al. Food groups and risk of benign prostatic hyperplasia. Urology. 2006;67:73–79
  63. Yang YJ, Lee SH, Hong SJ, Chung BC. Comparison of fatty acid profiles in the serum of patients with prostate cancer and benign prostatic hyperplasia. Clin Biochem. 1999;32:405–409
  64. Rohrmann S, Giovannucci E, Willett WC, Platz EA. Fruit and vegetable consumption, intake of micronutrients, and benign prostatic hyperplasia in US men. Am J Clin Nutr. 2007;85:523–529
  65. Demark-Wahnefried W, Robertson CN, Walther PJ, Polascik TJ, Paulson DF, Vollmer RT. Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen. Urology. 2004;63:900–904
  66. Tariq N, Jenkins DJA, Vidgen E, et al. Effect of soluble fiber diets on serum prostate specific antigen in men. J Urol. 2000;163:114–118
  67. Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia (BPH). N Engl J Med. 2006;354:557–566
  68. Ernst E. The risk-benefit profile of commonly used herbal therapies: ginkgo, St. John's wort, ginseng, echinacea, saw palmetto, and kava. Ann Intern Med. 2002;136:42–53
  69. Martinez M, Maislos S, Rayford W. How to engage the Latino or African American patient with benign prostatic hyperplasia: crossing socioeconomic and cultural barriers. Am J Med. 2008;121:S11–S17[suppl]
  70. Weinrich S, Priest JH, Moyad MA, Weinrich MC. Intake of selected nutritional supplements by African-American men. Urology. 2004;64:1094–1097
  71. AUA Practice Guidelines Committee. AUA Guideline on management of benign prostatic hyperplasia (2003) (Chapter 1: diagnosis and treatment recommendations). J Urol. 2003;170:530–547
  72. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta-carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report Number 8. Arch Ophthalmol. 2001;119:1417–1436
  73. Johnson AR, Munoz A, Gottlieb JL, Jarrard DF. High dose zinc increases hospital admissions due to genitourinary complications. J Urol. 2007;177:639–643
  74. Lagiou P, Wuu J, Trichopoulou A, Hsien CC, Adami HO, Trichopoulas D. Diet and benign prostatic hyperplasia: a study in Greece. Urology. 1999;54:284–290
  75. Leitzmann MF, Stampfer MJ, Wu K, Colditz GA, Willett WC, Giovannucci EL. Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst. 2003;95:1004–1007
  76. Moyad MA. Zinc for prostate disease and other conditions: a little evidence, a lot of hype, and a significant potential problem. Urol Nurs. 2004;24:49–52
  77. Chandra RK. Excessive intake of zinc impairs immune responses. JAMA. 1984;252:1443–1446
  78. Food and Nutrition Board, National Academy of Sciences. Dietary Reference Intakes For Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, And Zinc. In: Washington, DC: National Academy Press; 2001;p. 177–204351-398
  79. Huff JD, Keung YK, Thakuri M, et al. Copper deficiency causes reversible myelodysplasia. Am J Hematol. 2007;82:625–630
  80. Kumar N. Copper deficiency myelopathy (human swayback). Mayo Clin Proc. 2006;81:1371–1384
  81. Willis MS, Monaghan SA, Miller ML, et al. Zinc-induced copper deficiency: a report of three cases initially recognized on bone marrow examination. Am J Clin Pathol. 2005;123:125–131
  82. Fagelman E, Lowe FC. Herbal medications in the treatment of benign prostatic hyperplasia (BPH). Urol Clin North Am. 2002;29:23–29
  83. Corbie-Smith G, Thomas SB, St. George DM. Distrust, race, and research. Arch Intern Med. 2002;162:2458–2463

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(08)00511-1

doi: 10.1016/j.amjmed.2008.05.025

The American Journal of Medicine
Volume 121, Issue 8, Supplement 2 , Pages S34-S42 , August 2008

Article Tools